Chai Phua: 1st Publicly Funded Hemgenix Treatment for Hemophilia B in Canada Marks Historic Gene Therapy Milestone
Chai Phua, Associate Professor at Schulich School of Medicine and Dentistry, shared on LinkedIn:
”A historic milestone for bleeding disorders care in Canada.
Last week, the first publicly funded Canadian patient received Hemgenix for Hemophilia B at London Health Sciences Centre.
While this moment represents a major step forward in gene therapy and hemophilia B care, it also reflects decades of foundational work by leaders, clinicians, researchers, nurses, hemostasis laboratories, blood banks, patient advocates, and the broader bleeding disorders community across Canada who helped build the systems, expertise, and advocacy needed to make innovative therapies like this possible.
Most importantly, this milestone represents hope not only for one patient, but for the future of innovative therapies in rare diseases across Canada.
Thank you to everyone who helped make this possible.”
Stay updated with Hemostasis Today.
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026